CZ307511B6 - Fluorescenční konjugát kyseliny hyaluronové nebo jeho sůl, hydrofobizovaný konjugát, způsoby jejich přípravy a použití - Google Patents

Fluorescenční konjugát kyseliny hyaluronové nebo jeho sůl, hydrofobizovaný konjugát, způsoby jejich přípravy a použití Download PDF

Info

Publication number
CZ307511B6
CZ307511B6 CZ2015-936A CZ2015936A CZ307511B6 CZ 307511 B6 CZ307511 B6 CZ 307511B6 CZ 2015936 A CZ2015936 A CZ 2015936A CZ 307511 B6 CZ307511 B6 CZ 307511B6
Authority
CZ
Czechia
Prior art keywords
conjugate
hyaluronic acid
salt
fluorescent
formula
Prior art date
Application number
CZ2015-936A
Other languages
Czech (cs)
English (en)
Other versions
CZ2015936A3 (cs
Inventor
Eva Achbergerová
Daniela Šmejkalová
Gloria Huerta-Angeles
Karel SouÄŤek
Martina Hermannová
Vladimír Velebný
Original Assignee
Contipro A.S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Contipro A.S. filed Critical Contipro A.S.
Priority to CZ2015-936A priority Critical patent/CZ307511B6/cs
Priority to DK16840310.3T priority patent/DK3393527T3/da
Priority to HUE16840310A priority patent/HUE045756T2/hu
Priority to EP16840310.3A priority patent/EP3393527B1/en
Priority to US16/061,748 priority patent/US20190001000A1/en
Priority to KR1020187021096A priority patent/KR20180096761A/ko
Priority to RU2018123820A priority patent/RU2018123820A/ru
Priority to JP2018533195A priority patent/JP2019501262A/ja
Priority to BR112018012554A priority patent/BR112018012554A2/pt
Priority to PL16840310T priority patent/PL3393527T3/pl
Priority to ES16840310T priority patent/ES2751091T3/es
Priority to PCT/CZ2016/050048 priority patent/WO2017108015A1/en
Publication of CZ2015936A3 publication Critical patent/CZ2015936A3/cs
Publication of CZ307511B6 publication Critical patent/CZ307511B6/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1863—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CZ2015-936A 2015-12-23 2015-12-23 Fluorescenční konjugát kyseliny hyaluronové nebo jeho sůl, hydrofobizovaný konjugát, způsoby jejich přípravy a použití CZ307511B6 (cs)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CZ2015-936A CZ307511B6 (cs) 2015-12-23 2015-12-23 Fluorescenční konjugát kyseliny hyaluronové nebo jeho sůl, hydrofobizovaný konjugát, způsoby jejich přípravy a použití
DK16840310.3T DK3393527T3 (da) 2015-12-23 2016-12-22 Fluorescerende cypatkonjugat af hyaluronsyre eller salt deraf, konjugat der er gjort hydrofobt, fremgangsmåder til fremstilling og anvendelse deraf
HUE16840310A HUE045756T2 (hu) 2015-12-23 2016-12-22 Hialuronsav vagy annak sójának fluoreszcens cypate konjugátuma, hidrofóbizált konjugátum, eljárás ezek elõállítására és alkalmazására
EP16840310.3A EP3393527B1 (en) 2015-12-23 2016-12-22 Fluorescent cypate conjugate of hyaluronic acid or salt thereof, hydrophobized conjugate, methods of preparation and use thereof
US16/061,748 US20190001000A1 (en) 2015-12-23 2016-12-22 Fluorescent Cypate Conjugate of Hyaluronic Acid or Salt Thereof, Hydrophobized Conjugate, Methods of Preparation and Use Thereof
KR1020187021096A KR20180096761A (ko) 2015-12-23 2016-12-22 히알루론산 또는 이의 염의 형광 접합체, 소수성화된 접합체, 제조 방법 및 용도
RU2018123820A RU2018123820A (ru) 2015-12-23 2016-12-22 Флуоресцентный конъюгат гиалуроновой кислоты или ее соли, гидрофобизованный конъюгат, способы его получения и применение
JP2018533195A JP2019501262A (ja) 2015-12-23 2016-12-22 ヒアルロン酸又はその塩の蛍光Ｃｙｐａｔｅ複合体，疎水化複合体，それらの調製方法及び使用
BR112018012554A BR112018012554A2 (pt) 2015-12-23 2016-12-22 conjugado fluorescente de ácido hialurônico ou seu sal, derivado hidrofobizado de conjugado fluorescente de ácido hialurônico ou seu sal, método de preparação do conjugado fluorescente, método de preparação do derivado hidrofobizado do conjugado fluorescente, composição a base do agregado de derivado hidrofobizado do conjugado fluorescente
PL16840310T PL3393527T3 (pl) 2015-12-23 2016-12-22 Fluorescencyjny koniugat cypate i kwasu hialuronowego lub jego soli, hydrofobizowany koniugat, sposoby wytwarzania i jego zastosowanie
ES16840310T ES2751091T3 (es) 2015-12-23 2016-12-22 Conjugado fluorescente de cypate y de ácido hialurónico o sal del mismo, conjugado hidrofobizado, métodos de preparación y uso del mismo
PCT/CZ2016/050048 WO2017108015A1 (en) 2015-12-23 2016-12-22 Fluorescent cypate conjugate of hyaluronic acid or salt thereof, hydrophobized conjugate, methods of perparation and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CZ2015-936A CZ307511B6 (cs) 2015-12-23 2015-12-23 Fluorescenční konjugát kyseliny hyaluronové nebo jeho sůl, hydrofobizovaný konjugát, způsoby jejich přípravy a použití

Publications (2)

Publication Number Publication Date
CZ2015936A3 CZ2015936A3 (cs) 2017-07-07
CZ307511B6 true CZ307511B6 (cs) 2018-10-31

Family

ID=59089116

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ2015-936A CZ307511B6 (cs) 2015-12-23 2015-12-23 Fluorescenční konjugát kyseliny hyaluronové nebo jeho sůl, hydrofobizovaný konjugát, způsoby jejich přípravy a použití

Country Status (12)

Country Link
US (1) US20190001000A1 (https=)
EP (1) EP3393527B1 (https=)
JP (1) JP2019501262A (https=)
KR (1) KR20180096761A (https=)
BR (1) BR112018012554A2 (https=)
CZ (1) CZ307511B6 (https=)
DK (1) DK3393527T3 (https=)
ES (1) ES2751091T3 (https=)
HU (1) HUE045756T2 (https=)
PL (1) PL3393527T3 (https=)
RU (1) RU2018123820A (https=)
WO (1) WO2017108015A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115501204B (zh) * 2022-10-25 2023-07-21 河北工业大学 一种用于级联递送药物的透明质酸纳米给药系统的制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008025000A2 (en) * 2006-08-24 2008-02-28 Baylor College Of Medicine Imaging agents for functional imaging of lymphatic structures
US20120165646A1 (en) * 2010-12-27 2012-06-28 Canon Kabushiki Kaisha Composite particle, contrast agent for photoacoustic imaging, and photoacoustic imaging method
WO2014028861A1 (en) * 2012-08-17 2014-02-20 Apellis Pharmaceuticals, Inc. Detection of high risk drusen
WO2014129674A1 (en) * 2013-02-22 2014-08-28 Canon Kabushiki Kaisha Near-infrared dye-conjugated hyaluronic acid derivative and contrast agent for optical imaging including them

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180087B1 (en) 2000-01-18 2001-01-30 Mallinckrodt Inc. Tunable indocyanine dyes for biomedical applications
US6669926B1 (en) 2000-10-16 2003-12-30 Mallinckrodt, Inc. Hydrophilic light absorbing indole compounds for determination of physiological function in critically ill patients
WO2006078914A1 (en) * 2005-01-21 2006-07-27 Washington University In St. Louis Compounds having rd targeting motifs
US8758727B2 (en) 2008-03-31 2014-06-24 University Of Louisville Research Foundation, Inc. Site specific fluorescence and contrast marker for same
CZ305040B6 (cs) 2010-09-14 2015-04-08 Contipro Biotech S.R.O. Způsob přípravy vysoce substituovaných amidů kyseliny hyaluronové
KR20130085294A (ko) * 2012-01-19 2013-07-29 충남대학교산학협력단 림프노드 탐지용 형광 고분자 나노젤 및 이를 이용한 림프노드 확인 방법
CZ304654B6 (cs) 2012-11-27 2014-08-20 Contipro Biotech S.R.O. Nanomicelární kompozice na bázi C6-C18-acylovaného hyaluronanu, způsob přípravy C6-C18-acylovaného hyaluronanu, způsob přípravy nanomicelární kompozice a stabilizované nanomicelární kompozice a použití

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008025000A2 (en) * 2006-08-24 2008-02-28 Baylor College Of Medicine Imaging agents for functional imaging of lymphatic structures
US20120165646A1 (en) * 2010-12-27 2012-06-28 Canon Kabushiki Kaisha Composite particle, contrast agent for photoacoustic imaging, and photoacoustic imaging method
WO2014028861A1 (en) * 2012-08-17 2014-02-20 Apellis Pharmaceuticals, Inc. Detection of high risk drusen
WO2014129674A1 (en) * 2013-02-22 2014-08-28 Canon Kabushiki Kaisha Near-infrared dye-conjugated hyaluronic acid derivative and contrast agent for optical imaging including them

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
K. Miki et al: "Near-Infrared Dye-Conjugated Amphiphilic Hyaluronic Acid Derivatives as a Dual Contrast Agent for In Vivo Optical and Photoacoustic Tumor Imaging" Biomacromolecules 16, 219-227 (2015) *
W. Wang et al.: "Developing Fluorescent Hyaluronan Analogs for Hyaluronan Studies" Molecules 17 (2) 1520-1534 (2012) *
Y. Zhang et al: "Polymeric nanocarriers incorporating near-infrared absorbing agents for potent phothothermal therapy of cancer" Polymer Journal 48, 589-603 (2016) (on-line publ. 16.12.2015) *
Z. Zhang, S. Achilefu: "Design, synthesis and evaluation of near-infrared fluorescent pH indicators in a physiologically relevant range"Chem. Commun. 5887-5889 (2005) *

Also Published As

Publication number Publication date
JP2019501262A (ja) 2019-01-17
BR112018012554A2 (pt) 2018-12-04
HUE045756T2 (hu) 2020-01-28
WO2017108015A1 (en) 2017-06-29
US20190001000A1 (en) 2019-01-03
DK3393527T3 (da) 2019-10-07
EP3393527B1 (en) 2019-08-28
ES2751091T3 (es) 2020-03-30
EP3393527A1 (en) 2018-10-31
KR20180096761A (ko) 2018-08-29
RU2018123820A3 (https=) 2020-03-03
RU2018123820A (ru) 2019-12-30
PL3393527T3 (pl) 2020-03-31
CZ2015936A3 (cs) 2017-07-07

Similar Documents

Publication Publication Date Title
Yang et al. Tumor microenvironment (TME)-activatable circular aptamer-PEG as an effective hierarchical-targeting molecular medicine for photodynamic therapy
ES2863982T3 (es) Formación de imágenes fluorescentes ópticas que utiliza colorantes cianina
Liang et al. Activatable near infrared dye conjugated hyaluronic acid based nanoparticles as a targeted theranostic agent for enhanced fluorescence/CT/photoacoustic imaging guided photothermal therapy
Duo et al. Patient-derived microvesicles/AIE luminogen hybrid system for personalized sonodynamic cancer therapy in patient-derived xenograft models
Liu et al. Photosensitizer-conjugated redox-responsive dextran theranostic nanoparticles for near-infrared cancer imaging and photodynamic therapy
EP2682131B1 (en) Switching-type fluorescent nanoparticle probe, and fluorescent molecular imaging method using same
CN102438659A (zh) 光学成像剂
JP6230443B2 (ja) 近赤外色素結合ヒアルロン酸誘導体およびそれを有する光イメージング用造影剤
Lv et al. Lactose substituted zinc phthalocyanine: A near infrared fluorescence imaging probe for liver cancer targeting
PT988060E (pt) ''compostos corantes lábeis na presença de ácidos e dissociáveis enzimaticamente para o diagnóstico com luz de infravermelhos próximos e para o uso em terapia''
Hu et al. 6-Aminocaproic acid as a linker to improve near-infrared fluorescence imaging and photothermal cancer therapy of PEGylated indocyanine green
Ding et al. Dextran-based micelles for combinational chemo-photodynamic therapy of tumors via in vivo chemiluminescence
KR101183732B1 (ko) 광역학 진단 또는 치료를 위한 아세틸화된 다당류 및 광감작제가 결합된 결합체 및 이의 제조방법
KR102280761B1 (ko) 후코이단 기반의 쎄라그노시스 조성물
Xie et al. Progress and challenges of water-soluble NIR-II organic fluorophores for fluorescence imaging in vivo
Yuan et al. Sharp pH-sensitive amphiphilic polypeptide macrophotosensitizer for near infrared imaging-guided photodynamic therapy
KR100825939B1 (ko) 근적외선 형광체가 결합된 양친성 고분자의 나노 입자를포함하는 암 진단용 조영제
EP3393527B1 (en) Fluorescent cypate conjugate of hyaluronic acid or salt thereof, hydrophobized conjugate, methods of preparation and use thereof
KR102041246B1 (ko) 양쪽이온성 알긴산 유도체 및 이를 포함하는 조영제 조성물
CN116077682B (zh) 一种顺铂前药诊疗探针P-CyPt及其制备方法和应用
Chen et al. Dual fluorescence nano-conjugates based on gold nanoclusters for tumor-targeting imaging
WO2012038489A1 (en) Vascular imaging agents
KR102238174B1 (ko) 후코이단 기반의 쎄라그노시스 조성물
KR20150095108A (ko) 히알루로니다제의 생체 내 활성 모니터링을 위한 나노하이드로젤 및 그 제조 방법
EP3452091A1 (en) Nano-systems for therapy and/or diagnosis and/or therapy monitoring and/or theranostics of disease

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of fee

Effective date: 20221223